CARsgen Therapeutics Holdings Ltd. (CRTHF) Stock Statistics & Valuation Metrics

CARsgen Therapeutics Holdings Ltd. has a market cap or net worth of $805.12M. The enterprise value is $6.32B.

Market Cap

$805.12M

Enterprise Value

$6.32B

CARsgen Therapeutics Holdings Ltd. has 594,248,900 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

594,248,900

Owned by Insiders

―

Owned by Institutions

―

CARsgen Therapeutics Holdings Ltd.’s return on equity (ROE) is -0.12 and return on invested capital (ROIC) is -9.36%.

Return on Equity (ROE)

-0.12

Return on Assets (ROA)

-0.08

Return on Invested Capital (ROIC)

-9.36%

Return on Capital Employed (ROCE)

-0.10

Revenue Per Employee

296.37K

Profits Per Employee

-230.80K

Employee Count

424

Asset Turnover

0.10

Inventory Turnover

6.40

The current PE Ratio of CARsgen Therapeutics Holdings Ltd. is -56.08. CARsgen Therapeutics Holdings Ltd.’s PEG ratio is -0.55.

PE Ratio

-56.08

PS Ratio

39.15

PB Ratio

4.51

Price to FCF

-28.66

Price to Operating Cash Flow

-28.43

PEG Ratio

-0.55

In the last 12 months, CARsgen Therapeutics Holdings Ltd. had revenue of 125.66M and earned -97.86M in profits. Earnings per share was -0.18.

Revenue

125.66M

Gross Profit

79.95M

Operating Income

-104.21M

Pretax Income

-102.91M

Net Income

-97.86M

EBITDA

-198.40M

Earnings Per Share (EPS)

-0.18

In the last 12 months, operating cash flow was -174.63M and capital expenditures 41.64M, giving a free cash flow of -186.66M billion.

Operating Cash Flow

-174.63M

Free Cash Flow

-186.66M

Free Cash Flow per Share

-0.34

CARsgen Therapeutics Holdings Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share

―

Dividend Yield

―

Payout Ratio

N/A

Free Cash Flow Yield

-3.49%

Earnings Yield

-1.79%

Beta

0.49

52-Week Price Change

167.77%

50-Day Moving Average

1.62

200-Day Moving Average

1.75

Relative Strength Index (RSI)

20.08

Average Volume (3m)

2,333

CARsgen Therapeutics Holdings Ltd. upcoming earnings date is Mar 23, 2027, TBA (Not Confirmed).

Last Earnings Date

Aug 19, 2026

Next Earnings Date

Mar 23, 2027

Ex-Dividend Date

―

CARsgen Therapeutics Holdings Ltd. as a current ratio of 5.73, with Debt / Equity ratio of 7.81%

Current Ratio

5.73

Quick Ratio

5.70

Debt to Market Cap

0.00

Net Debt to EBITDA

5.36

Interest Coverage Ratio

-15.11

In the past 12 months, CARsgen Therapeutics Holdings Ltd. has paid 0 in taxes.

Income Tax

0

Effective Tax Rate

0.00

CARsgen Therapeutics Holdings Ltd. EV to EBITDA ratio is -21.01, with an EV/FCF ratio of -21.55.

EV to Sales

29.44

EV to EBITDA

-21.01

EV to Free Cash Flow

-21.55

EV to Operating Cash Flow

-23.03

CARsgen Therapeutics Holdings Ltd. has $1.40B in cash and marketable securities with $71.98M in debt, giving a net cash position of $1.33B billion.

Cash & Marketable Securities

$1.40B

Total Debt

$71.98M

Net Cash

$1.33B

Net Cash Per Share

$2.23

Tangible Book Value Per Share

$1.98

Gross margin is 67.78%, with operating margin of -72.35%, and net profit margin of -65.17%.

Gross Margin

67.78%

Operating Margin

-72.35%

Pretax Margin

-71.93%

Net Profit Margin

-65.17%

EBITDA Margin

-140.12%

EBIT Margin

-161.33%

The average price target for CARsgen Therapeutics Holdings Ltd. is $1.76, which is 11.43% higher than the current price. The consensus rating is Moderate Sell

Price Target

$1.76

Price Target Upside

8.73% Upside

Analyst Consensus

Moderate Sell

Analyst Count

1

Revenue Growth Forecast

67.68%

EPS Growth Forecast

81.91%

Smart Score

3

AI Score

―